| Primary information |
|---|
| sequence ID | Seq_7270 |
| Peptide sequence | SLAELGGHLDQQVEE |
| CancerPDF_ID | CancerPDF_ID9241, CancerPDF_ID9559, |
| PMID | 24694173,21533267 |
| Protein Name | Apolipoprotein A-IV,Apolipoprotein A-IV |
| UniprotKB Entry Name | APOA4_HUMAN,APOA4_HUMAN |
| Fluid | Ascites fluid,Serum |
| M/Z | NA,812.89 |
| Charge | 1,2 |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | LTQ-Orbitrap XL,LC-MS |
| Peptide Identification technique | X tandem for peptide identification,LC/MS/MS |
| Quantification Technique | NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,1.49 |
| CancerPDF_ID | CancerPDF_ID9241, CancerPDF_ID9559, |
| p-Value | NA,NA |
| Software | "X tandem for peptide identification,Scaffold 2 software for any modification analysis",MASCOT |
| Length | 15,15 |
| Cancer Type | Ovarian cancer,Lung adenocarcinoma |
| Database | IPI00304273,Swissprot Database (57.4) |
| Modification | NA,NA |
| Number of Patients | 3 ovarian cancer patient and 3 non cancerous control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | Uniquely expressed in ovarian cancer patient,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |